Characterization and partial purification of a keratinocyte-derived growth factor with wound-healing properties.
We have previously described the mitogenic and wound-healing properties of keratinocyte-conditioned medium (KCM). In this study we investigated the effect of KCM on the activation of second messenger systems and the expression of proto-oncogene in cultured human skin fibroblasts. We also present a partial purification of the factor responsible for the mitogenic and wound-healing effects of KCM. KCM was shown to increase the expression of the proto-oncogenes c-fos, c-myc and c-jun. The effect of KCM on three second messenger systems was investigated. The extracellular release of choline metabolites was increased by 40 per cent when cells were stimulated with KCM whereas the formation of cAMP and hydrolysis of phosphatidyl inositol (PI) was unaffected. KCM was purified by ion exchange chromatography and filtration. The biologically active fraction was eluted from an SP column and retained its activity after filtration through a 3-kDa filter. The fraction was inactivated by heat and acid, indicative of a peptide origin. Furthermore, the active fraction was shown to increase the extracellular release of choline metabolites and to stimulate re-epithelialization in wounds in human skin in vitro comparable to KCM. The study indicates that human keratinocytes produce a < 3 kDa peptide which may be partly responsible for the growth stimulatory and wound-healing properties of KCM.
Kratz
G
G
Department of Plastic and Reconstructive Surgery, Karolinska Hospital, Stockholm, Sweden.
Jonzon
B
B
Hultgård-Nilsson
A
A
Haegerstrand
A
A
D016475:3T3 Cells / Q000737:chemistry / Q000166:cytology / Q000378:metabolism; D000143:Acids; D000818:Animals; D017077:Culture Media, Conditioned / Q000737:chemistry* / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D006133:Growth Substances / Q000737:chemistry / Q000302:isolation & purification*; D006358:Hot Temperature; D006801:Humans; D007295:Inositol Phosphates / Q000378:metabolism; D015603:Keratinocytes / Q000737:chemistry* / Q000166:cytology; D051379:Mice; D000090063:Proto-Oncogene Mas; D016760:Proto-Oncogene Proteins c-fos / Q000096:biosynthesis; D016755:Proto-Oncogene Proteins c-jun / Q000096:biosynthesis; D016271:Proto-Oncogene Proteins c-myc / Q000096:biosynthesis; D015290:Second Messenger Systems / Q000502:physiology; D012867:Skin / Q000166:cytology; D013936:Thymidine / Q000378:metabolism / Q000494:pharmacology; D014316:Tritium; D014945:Wound Healing / Q000187:drug effects / Q000502:physiology*
D000143:Acids; D017077:Culture Media, Conditioned; D006133:Growth Substances; D007295:Inositol Phosphates; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D016760:Proto-Oncogene Proteins c-fos; D016755:Proto-Oncogene Proteins c-jun; D016271:Proto-Oncogene Proteins c-myc; D014316:Tritium; D000242:Cyclic AMP; D013936:Thymidine